Demcizumab 产品活性：Demcizumab (OMP 21M18) 是一种抗 DLL4 单克隆抗体。Demcizumab 是一种有效的 Notch 通路抑制剂。Demcizumab 单独或联合化疗试剂对多种癌症模型有效。 产品来源： https://www.medchemexpress.cn/demcizumab.html 研究领域：Neuronal Signaling | Stem Cell/Wnt 作用靶点：Notch In Vitro: Demcizumab (0-100 μg/mL) binds to human DLL4 but not murine DLL4, and blocks DLL4 binding to Notch1 receptor in a FACS-binding assay. Demcizumab (20 μg/mL, 48 h) reduces HES1 and DTX1 mRNA expression in PDTALL cells. Demcizumab (0-80 μg/mL, 1 or 2 or 3 days) promotes cell death and early apoptosis in PDTALL13 cells. In Vivo: Demcizumab (10 mg/kg, i.p., once a week) together with Irinotecan (7.5 mg/kg) show a significant antitumor effect in KRASWT and KRASMT CRC xenografts. Demcizumab is efficacious alone or in combination with Irinotecan (7.5 mg/kg) in OMP-C8 colon tumors. Demcizumab (20 mg/kg/week, i.p.) increases mice survival in irradiated NRG mice injected PDTALL13 cells. 相关产品：DAPT | Valproic acid | LY-411575 | Jagged-1 (188-204) (TFA) | YO-01027 | RO4929097 | Tangeretin | Limantrafin | Carvacrol | Tarlatamab | RBPJ Inhibitor-1 | Crenigacestat | IMR-1 | Semagacestat | Prednisone acetate | Psoralidin | Bruceine D | FLI-06 | BMS-906024 | Rovalpituzumab | Yhhu-3792 | Avagacestat | JI051 | ZLDI-8 | BMS-983970 | LY900009 | Brontictuzumab | Z-Ile-Leu-aldehyde | BMS-986115 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。